HC Wainwright assumed coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX) in a research report sent to investors on Monday, Benzinga reports. The brokerage issued a buy rating and a $23.00 target price on the stock.

A number of other brokerages have also weighed in on PTGX. BidaskClub raised Misonix from a buy rating to a strong-buy rating in a research note on Wednesday, July 3rd. Stifel Nicolaus raised Protagonist Therapeutics from a hold rating to a buy rating and increased their price target for the stock from $11.00 to $17.00 in a research note on Wednesday, May 8th. Zacks Investment Research lowered HEXO from a hold rating to a sell rating in a research note on Wednesday, May 15th. Finally, ValuEngine raised VESTAS WIND SYS/ADR from a hold rating to a buy rating in a research note on Thursday, May 9th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $17.17.

PTGX stock traded up $0.44 on Monday, reaching $13.65. The company had a trading volume of 887,052 shares, compared to its average volume of 203,208. Protagonist Therapeutics has a 1 year low of $5.49 and a 1 year high of $14.36. The company has a current ratio of 5.02, a quick ratio of 5.02 and a debt-to-equity ratio of 0.07. The firm’s fifty day moving average price is $11.69. The company has a market capitalization of $319.36 million, a P/E ratio of -7.84 and a beta of 1.88.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Wednesday, May 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.01. Protagonist Therapeutics had a negative return on equity of 40.78% and a negative net margin of 209.02%. The firm had revenue of $1.56 million for the quarter, compared to analyst estimates of $2.50 million. As a group, equities analysts anticipate that Protagonist Therapeutics will post -2.36 EPS for the current year.

Several institutional investors have recently modified their holdings of PTGX. Laurion Capital Management LP increased its holdings in shares of Protagonist Therapeutics by 400.8% during the 1st quarter. Laurion Capital Management LP now owns 85,641 shares of the company’s stock worth $1,077,000 after purchasing an additional 68,541 shares during the period. Bank of Montreal Can increased its stake in Protagonist Therapeutics by 1,675.5% in the first quarter. Bank of Montreal Can now owns 11,026 shares of the company’s stock valued at $139,000 after acquiring an additional 10,405 shares during the period. Tibra Equities Europe Ltd bought a new stake in Protagonist Therapeutics in the first quarter valued at about $410,000. Perceptive Advisors LLC bought a new stake in Protagonist Therapeutics in the fourth quarter valued at about $9,190,000. Finally, D. E. Shaw & Co. Inc. increased its stake in Protagonist Therapeutics by 75.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 19,645 shares of the company’s stock valued at $132,000 after acquiring an additional 8,450 shares during the period. 64.40% of the stock is currently owned by institutional investors.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Recommended Story: Systematic Risk

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.